Lyra Therapeutics, Inc.

LYRA

Lyra Therapeutics, Inc.

LYRA

Insider Sentiment (TTM):

Last Purchase:2023-11-10Last Sale:2026-01-06Shares Purchased (TTM):0Shares Sold (TTM):52,783

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:104,059Shares Outstanding:1,553,473Institutional Ownership Pct.:6.70%

Earnings Market Reaction:

Filing Date:2026-03-31Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	16	22	30	32	41	24	32	16	22	25	54	22
Prepaid Expense And Other Assets Current	0	1	1	2	2	3	2	2	2	2	2	2
Short Term Investments	0	-	-	-	0	28	36	71	80	78	62	61
Restricted Cash Current	-	-	-	-	-	-	-	-	-	-	0	-
Assets Current	16	23	31	34	43	54	69	89	105	105	118	85
Property Plant And Equipment Net	1	1	1	1	1	2	2	4	2	1	1	2
Operating Lease Right Of Use Asset	17	18	18	19	20	21	21	46	33	6	1	2
Restricted Cash Noncurrent	2	2	2	2	2	2	2	2	1	1	1	1
Assets	36	44	53	56	66	79	95	142	143	121	126	94
Liabilities And Stockhold…
Liabilities Current
Other Assets Noncurrent	-	-	-	-	0	-	-	1	1	7	4	4
Accounts Payable Current	1	1	1	1	1	2	5	3	3	5	4	4
Restructuring Reserve Current	3	3	3	4	4	5	3	-	-	-	-	-
Accrued Liabilities And Other Liabilities	1	-	-	-	3	-	-	-	9	-	-	-
Operating Lease Liability Current	5	5	5	4	4	4	4	5	5	1	2	2
Deferred Revenue Current	-	0	0	0	0	1	1	1	2	2	1	2
Liabilities Current	10	9	11	11	13	15	19	19	20	19	14	14
Operating Lease Liability Noncurrent	25	27	28	29	30	31	32	33	21	5	-	0
Deferred Revenue Noncurrent	12	12	12	12	12	12	12	12	12	12	13	13
Liabilities	47	48	51	52	55	58	64	64	53	36	27	28
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	423	422	422	417	416	414	413	411	401	380	379	331
Retained Earnings Accumulated Deficit	-434	-427	-421	-413	-405	-394	-382	-334	-311	-296	-281	-265
Stockholders Equity	-11	-4	2	4	12	21	31	78	89	84	99	66
Liabilities And Stockholders Equity	36	44	53	56	66	79	95	142	143	121	126	94
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	0	0	-0	0	0	-0	-0	-0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	2	2	2	1	1	1	1	1	1	1	1	1
Shares Outstanding	2	2	2	1	1	1	1	1	1	1	1	1
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	-3.33%	78.63%	55.88%	1.48%	3.70%	-14.67%	10.05%	-18.56%	-54.12%	44.69%	52.72%	38.46%
2024	-93.69%	-94.76%	-94.57%	-4.85%	-17.17%	-9.67%	-21.85%	-24.36%	-33.53%	-31.09%	-38.11%	-43.66%
2023	4.87%	53.93%	23.60%	8.39%	21.43%	-8.39%	23.55%	78.84%	64.85%	-15.38%	-94.03%	-94.87%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	1.71	2.43	2.78	2.96	3.41	3.64	3.60	4.78	5.35	5.45	8.38	5.99
Quick Ratio	1.67	2.33	2.67	2.77	3.21	3.45	3.50	4.65	5.24	5.33	8.25	5.84
Working Capital	6.75M	13.54M	19.90M	22.44M	30.39M	39.49M	50.16M	70.72M	85.22M	85.69M	104.14M	70.65M
Leverage & Debt
Debt to Equity	-4.37	-11.10	31.41	13.54	4.72	2.82	2.05	0.83	0.59	0.43	0.27	0.42
Debt Ratio	1.30	1.10	0.97	0.93	0.83	0.74	0.67	0.45	0.37	0.30	0.22	0.30
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.01	0.02
Per Share Metrics
Diluted EPS TTM	-18.62	-18.64	-28.80	-60.47	-71.75	-74.56	-77.44	-53.80	-62.93	-54.22	-69.69	-80.94
Free Cash Flow Per Share TTM	-18.65	-19.36	-31.99	-44.75	-57.30	-63.44	-61.90	-57.07	-64.60	-49.78	-61.03	-64.41
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-7,794.47%	-5,885.33%	-5,391.82%	-6,891.56%	-6,280.83%	-6,894.43%	-5,813.30%	-4,364.94%	-4,308.09%	-4,623.89%	-5,153.23%	-4,727.51%
Net Profit Margin TTM	-7,266.08%	-5,491.17%	-5,043.64%	-6,711.39%	-6,090.94%	-6,635.76%	-5,570.88%	-4,099.82%	-4,023.11%	-4,340.06%	-4,917.12%	-4,568.74%
Growth Metrics
Net Revenue Growth (1Y)	-74.05%	-59.21%	-57.69%	-29.46%	-1.54%	3.37%	47.01%	28.74%	14.31%	-12.32%	-3.13%	73.31%
Net Income Growth (1Y)	-69.05%	-66.25%	-61.70%	15.47%	49.07%	58.05%	66.56%	15.52%	13.39%	12.99%	19.48%	25.20%
EPS Growth (1Y)	-74.05%	-75.00%	-62.82%	12.40%	14.02%	37.52%	11.13%	-33.53%	-31.16%	-26.94%	-7.14%	-55.78%
Valuation Metrics
P/E TTM	-0.17	-0.35	-0.31	-0.10	-0.14	-0.17	-0.18	-5.78	-4.16	-3.61	-2.95	-1.24
P/B TTM	-0.45	-2.67	7.45	2.14	1.16	0.82	0.58	5.14	2.92	2.64	1.82	1.12
P/S TTM	12.02	19.23	15.69	7.01	8.76	11.44	9.95	236.99	167.51	156.49	145.00	56.73
Market Cap	4.78M	11.54M	12.08M	8.31M	13.44M	16.82M	18.11M	398.15M	260.97M	222.69M	179.51M	74.03M
Enterprise Value	-11.11M	-10.52M	-17.70M	-23.43M	-27.14M	-6.98M	-13.79M	382.35M	238.62M	197.84M	125.15M	52.01M
Calculated Values
Free Cash Flow TTM	-28.98M	-34.22M	-43.14M	-58.85M	-74.61M	-83.05M	-81.03M	-73.06M	-64.35M	-56.70M	-53.32M	-47.45M
Net Debt	-15.89M	-22.06M	-29.78M	-31.74M	-40.58M	-23.80M	-31.91M	-15.80M	-22.35M	-24.85M	-54.36M	-22.02M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-06Sale

Owner: Cavalier, Jason

Title: Chief Financial Officer

Shares: 769

Price/Share: $3.36

Value: $2,583.84

Shares Owned: 518,547

Relationship: Officer

Ownership: Direct

2026-01-06Sale

Owner: Palasis, Maria

Title: President & CEO

Shares: 1,702

Price/Share: $3.36

Value: $5,718.72

Shares Owned: 1,096,733

Relationship: Director,Officer

Ownership: Direct

2025-11-13Sale

Owner: Perceptive, Advisors Llc,…

Title: -

Shares: 31,810

Price/Share: $3.90

Value: $124,059.00

Shares Owned: 14,026

Relationship: TenPercentOwner

Ownership: Indirect

2025-11-10Sale

Owner: Edelman, Joseph, Percepti…

Title: -

Shares: 18,502

Price/Share: $4.54

Value: $83,999.08

Shares Owned: 18,659

Relationship: TenPercentOwner

Ownership: Indirect

2025-07-10Sale

Owner: Cavalier, Jason

Title: Chief Financial Officer

Shares: 684

Price/Share: $8.91

Value: $6,094.44

Shares Owned: 519,316

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-06	Cavalier, Jason	Officer	Chief Financial Officer	Direct	Sale	769	3.36	$2,583.84	518,547	4
2026-01-06	Palasis, Maria	Director,Officer	President & CEO	Direct	Sale	1,702	3.36	$5,718.72	1,096,733	4
2025-11-13	Perceptive, Advisors Llc,…	TenPercentOwner	-	Indirect	Sale	31,810	3.90	$124,059.00	14,026	4
2025-11-10	Edelman, Joseph, Percepti…	TenPercentOwner	-	Indirect	Sale	18,502	4.54	$83,999.08	18,659	4
2025-07-10	Cavalier, Jason	Officer	Chief Financial Officer	Direct	Sale	684	8.91	$6,094.44	519,316	4
2025-07-10	Palasis, Maria	Director,Officer	President & CEO	Direct	Sale	1,565	8.91	$13,944.15	1,098,435	4
2023-11-10	Waksal, Harlan	Director,Officer	Executive Chair	Direct	Purchase	25,000	2.96	$74,000.00	261,966	4
2023-05-31	North, Bridge Venture Par…	TenPercentOwner	-	Indirect	Purchase	1,805,416	2.43	$4,387,160.88	2,521,745	4
2023-05-31	Anderson, Edward T	Director,TenPercentOwner	-	Indirect	Purchase	1,805,416	2.43	$4,387,160.88	2,521,745	4
2023-05-31	Perceptive, Ls (A), Llc, …	TenPercentOwner	-	Indirect	Purchase	3,610,832	2.49	$8,990,971.68	11,469,117	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

6.70%

Inst. Shares: 104,059

Shares Outstanding: 1,553,473

2025-12-31

15.62%

Inst. Shares: 242,614

Shares Outstanding: 1,553,473

2025-09-30

25.38%

Inst. Shares: 448,586

Shares Outstanding: 1,767,814

2025-06-30

36.56%

Inst. Shares: 492,992

Shares Outstanding: 1,348,630

2025-03-31

38.55%

Inst. Shares: 506,978

Shares Outstanding: 1,315,157

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	104,059	1,553,473	6.70%
2025-12-31	242,614	1,553,473	15.62%
2025-09-30	448,586	1,767,814	25.38%
2025-06-30	492,992	1,348,630	36.56%
2025-03-31	506,978	1,315,157	38.55%
2024-12-31	531,186	1,302,277	40.79%
2024-09-30	639,644	1,309,134	48.86%
2024-06-30	623,714	1,309,193	47.64%
2024-03-31	905,676	1,280,227	70.74%
2023-12-31	844,784	996,086	84.81%
2023-09-30	637,187	1,139,074	55.94%
2023-06-30	672,522	873,528	76.99%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Lyra Therapeutics, Inc. (LYRA) — SEC Financial Statements & Analysis

Lyra Therapeutics, Inc. (LYRA) is a surgical & medical instruments & apparatus company, incorporated in DE. Lyra Therapeutics, Inc. trades on OTC as: LYRA. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Lyra Therapeutics, Inc. reported a -74.05% year-over-year revenue growth, a Debt-to-Equity ratio of -4.37x, a Price-to-Sales (P/S) ratio of 12.02x (TTM), a Price-to-Book (P/B) ratio of -0.45x (TTM), at a market cap of $4.78M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -74.05%
Debt To Equity: -4.37x
P/S TTM: 12.02x
P/B TTM: -0.45x
Market Cap: $4.78M

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Lyra Therapeutics, Inc. in?

Lyra Therapeutics, Inc. (LYRA) operates in the Surgical & Medical Instruments & Apparatus industry.

What is LYRA's market cap?

Lyra Therapeutics, Inc. (LYRA) has a market capitalization of $4.78M as of 2025-12-31.

What exchange does LYRA trade on?

Lyra Therapeutics, Inc. (LYRA) trades on the OTC.

Where is Lyra Therapeutics, Inc. incorporated?

Lyra Therapeutics, Inc. is incorporated in DE.